Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 212, Issue -, Pages S210-S218Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiv255
Keywords
Ebola; glycoprotein; entry; IFITM; interferon
Categories
Funding
- German Research Foundation [PO 716/8-1]
- German Ministry for Research and Education (subproject within EBOCON)
- National Institute of Allergy and Infectious Diseases [R21AI107165]
- Leibniz Graduate School Emerging Infectious Diseases
- Leibniz Foundation
Ask authors/readers for more resources
Ebolaviruses are highly pathogenic in humans and nonhuman primates and pose a severe threat to public health. The interferon-induced transmembrane (IFITM) proteins can restrict entry of ebolaviruses, influenza A viruses, and other enveloped viruses. However, the breadth and mechanism of the antiviral activity of IFITM proteins are incompletely understood. Here, we employed ebolavirus glycoprotein-pseudotyped vectors and ebolavirus-like particles to address this question. We show that IFITM proteins inhibit the cellular entry of diverse ebolaviruses and demonstrate that type I interferon induces IFITM protein expression in macrophages, major viral targets. Moreover, we show that IFITM proteins block entry of influenza A viruses and ebolaviruses by different mechanisms and provide evidence that antibodies and IFITM proteins can synergistically inhibit cellular entry of ebolaviruses. These results provide insights into the role of IFITM proteins in infection by ebolaviruses and suggest a mechanism by which antibodies, though poorly neutralizing in vitro, might contribute to viral control in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available